CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA
Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and/or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.
1 . A method for treating fibromyalgia and its associated symptoms of pain, sleep disturbance and/or fatigue, comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in the form of a eutectic selected from the group consisting of a 75%±2% cyclobenzaprine and 25%±2% mannitol eutectic, a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic, a mixture of a 75%±2% cyclobenzaprine HCl and 25%±2% β-mannitol and a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic, and a granule comprising an outer layer of a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic and an inner layer of β-mannitol, and the one or more dosage units further comprising a basifying agent.
2 . The method for treating according to claim 1 , wherein the cyclobenzaprine HCl eutectic comprises a 75%±2% cyclobenzaprine and 25%±2% mannitol eutectic.
3 . (canceled)
4 . The method for treating according to claim 1 , wherein the one or more dosage units comprising the cyclobenzaprine HCl eutectic are two dosage units, each dosage unit comprising 2.8 mg of cyclobenzaprine HCl.
5 . A multiple-variable dose method for treating fibromyalgia and its associated symptoms of pain, sleep disturbance and/or fatigue in a subject in need thereof, comprising the transmucosal administration of:
one or more of a first dosage unit comprising 2.8 mg of cyclobenzaprine HCl to the subject daily for about two weeks; and
one or more of a second dosage unit comprising 5.6 mg of cyclobenzaprine HCl to the subject daily for as long as needed,
wherein the cyclobenzaprine HCl is in the form of a eutectic selected from the group consisting of a 75%±2% cyclobenzaprine and 25%±2% mannitol eutectic, a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic, a mixture of a 75%±2% cyclobenzaprine HCl and 25%±2% β-mannitol and a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic, and a granule comprising an outer layer of a 65%±2% cyclobenzaprine HCl and 35%±2% δ-mannitol eutectic and an inner layer of β-mannitol, and the dosage units further comprise a basifying agent.
6 . The method for treating according to claim 5 , wherein the one or more second dosage unit is administered following administration of the one or more first dosage unit.
7 . The method for treating according to claim 5 , wherein the cyclobenzaprine HCl of the first dosage unit and the cyclobenzaprine HCl of the second dosage unit are in the form of a eutectic comprising 75%±2% cyclobenzaprine and 25%±2% β-mannitol.
8 . (canceled)
9 . The method for treating according to claim 1 , wherein the one or more dosage units of cyclobenzaprine HCl eutectic are administered at bedtime.
10 . The method for treating according to claim 5 , wherein the one or more of the first dosage units, the one or more of the second dosage units comprising the cyclobenzaprine HCl eutectic, or both are administered at bedtime.
11 . The method for treating according to claim 1 , wherein said transmucosal administration comprises sublingual, buccal, intranasal or palatal administration.
12 . The method for treating according to claim 5 , wherein said transmucosal administration comprises sublingual, buccal, intranasal or palatal administration.
13 . The method for treating according to claim 1 , wherein the basifying agent is selected from a group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate, trisodium citrate, borate, hydroxide, silicate, nitrate, dissolved ammonia, bicarbonate, and sulfide.
14 . The method for treating according to claim 5 , wherein the basifying agent is selected from a group consisting of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, tripotassium phosphate, sodium carbonate, sodium bicarbonate, calcium carbonate, calcium bicarbonate, TRIS buffer, sodium dihydrogen phosphate, disodium hydrogen phosphate, trisodium phosphate, potassium carbonate, potassium bicarbonate, potassium acetate, sodium acetate, dipotassium citrate, tripotassium citrate, disodium citrate, trisodium citrate, borate, hydroxide, silicate, nitrate, dissolved ammonia, bicarbonate, and sulfide.
15 . The method for treating according to claim 1 , wherein the treatment reduces pain, improves sleep quality, reduces sleep disturbances or reduces fatigue.
16 . The method for treating according to claim 15 , wherein the pain is measured by daily diary pain severity score change from a baseline score as compared to a placebo group using a numerical rating scale.
17 . The method for treating according to claim 15 , wherein the pain is reduced by greater than 30%.
18 . The method for treating according to claim 5 , wherein treatment reduces pain, improves sleep quality, reduces sleep disturbances or reduces fatigue.
19 . The method for treating according to claim 18 , wherein the pain is reduced by greater than 30%.
20 . The method for treating according to claim 1 , wherein the subject is human.
21 .- 34 . (canceled)
35 . The method for treating according to claim 18 , wherein the pain is measured by daily diary pain severity score change from a baseline score as compared to a placebo group using a numerical rating scale.
36 . The method for treating according to claim 5 , wherein the subject is human.